Total operating expenses 404,164 276,404 39,445 ---------- ----------- ----------- Income (loss) from operations (183,259) 30,858 4,404 Other income (expenses): Late fees related to social security insurance (446) (213) (30) Government grants 14,628 3,864 551 Financial expenses - net (12,968) (6,573) (938) Fair value changes of warrant liability 6,851 315 45 Other income (expense) - net (149) (6,454) (921) Total other income (expense) - net 7,916 (9,061) (1,293) ---------- ----------- ----------- Income (loss) before income taxes (175,343) 21,797 3,111 Income tax benefit (expense) 820 (1,218) (174) ---------- ----------- ----------- Net income (loss) (174,523) 20,579 2,937 ---------- ----------- ----------- Net income (loss) attributable to Lakeshore Group (174,523) 20,579 2,937 ========== =========== =========== Net income (loss) (174,523) 20,579 2,937 Other comprehensive income (loss): Foreign currency translation adjustment 3,166 (4,900) (700) ---------- ----------- ----------- Total comprehensive income (loss) (171,357) 15,679 2,237 ========== =========== =========== Earnings (loss) per share: -- Basic and Diluted (1.88) 0.11 0.02 ========== =========== =========== Weighted average number of ordinary shares outstanding: -- Basic and Diluted 93,058,197 190,429,732 190,429,732 ========== =========== =========== Lakeshore Biopharma Co., Ltd Unaudited Reconciliations of Non-GAAP Results (All amounts in thousands) Six Months Ended September 30, ----------------------------------- 2023 2024 2024 ------------- ---------- ------- RMB RMB US$ Net income (loss) (174,523) 20,579 2,937 Add: income tax expense (benefit) (820) 1,218 174 Add: financial expenses - net 12,968 6,573 938 Add: depreciation and amortization 23,734 25,414 3,627 ------------- ---------- ------- EBITDA (138,641) 53,784 7,676 ============= ========== ======= Add: Share-based compensation expenses - 1,659 237 Add: late fees related to social security insurance 446 213 30 Add: other income (expense) - net 149 6,454 921 Add: fair value changes of warrant liability (6,851) (315) (45) Add: government grants (14,628) (3,864) (551) ------------- ---------- ------- Adjusted EBITDA (159,525) 57,931 8,268 ============= ========== ======= Six Months Ended September 30, ----------------------------------- 2023 2024 2024 ------------- ---------- ------- RMB RMB US$ Net income (loss) (174,523) 20,579 2,937 Add: share-based compensation expenses - 1,659 237 Add: loss on disposal of property, plant and equipment - 8,210 1,172 ------------- ---------- ------- Adjusted net income (loss) (174,523) 30,448 4,346 ============= ========== =======
View original content:https://www.prnewswire.com/news-releases/lakeshore-biopharma-reports-unaudited-financial-results-for-the-first-half-of-fiscal-year-2025-and-updates-full-year-guidance-302336215.html
SOURCE LakeShore Biopharma
/CONTACT: Yiyang Wang, ir@lakeshorebio.com
(END) Dow Jones Newswires
December 19, 2024 09:05 ET (14:05 GMT)
Comments